Using glucagon to enhance insulin absorption in type 1 diabetes
Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1
This study is testing if using small amounts of glucagon with insulin injections can help people with type 1 diabetes absorb insulin better.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | St. Olavs Hospital Academic / other |
| Locations | 1 site (Trondheim) |
| Trial ID | NCT05960565 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of microdoses of glucagon administered at the site of insulin injection in individuals with type 1 diabetes. Participants will attend the research facility on two separate days, where they will receive their regular meal insulin dose along with either glucagon or a placebo. Blood samples will be collected frequently to analyze glucose, insulin, and glucagon levels over a 3.5-hour period. The goal is to determine if glucagon can significantly enhance insulin absorption compared to insulin alone.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 70 with type 1 diabetes for at least one year and controlled HbA1c levels.
Not a fit: Patients who are pregnant, have chronic diseases, or known hypersensitivity to glucagon may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved insulin absorption and better blood glucose control for patients with type 1 diabetes.
How similar studies have performed: While this approach is novel, preliminary data from animal studies suggest potential success in enhancing insulin absorption.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1: Type 1 diabetes for at least 1 year. 2. Age 18 - 70 years. 3. Last known HbA1c \<86 mmol/mol. 4. Treated with continuous subcutaneous insulin infusion (CSII) by an insulin pump or multiple daily insulin injections (MDII). Exclusion Criteria: 1. Pregnant women or women trying to conceive. 2. Any chronic disease, including psychiatric illness, judged incompatible with participation in the study. 3. Unfit for participation for any reason judged by the investigators. 4. Known hypersensitivity to glucagon or any of the excipients of the drug formulation. 5. Known phaeochromocytoma. -
Where this trial is running
Trondheim
- Department of Endocrinology, St. Olavs Hospital — Trondheim, Norway (Recruiting)
Study contacts
- Principal investigator: Sven M Carlsen, MD, PhD — St. Olav's University Hospital
- Study coordinator: Sven M Carlsen, MD, PhD
- Email: sven.carlsen@ntnu.no
- Phone: +47 91769528
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.